Navigation Links
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:5/13/2008

s is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer ... recently participated in the American Urology Association’s (AUA) ... Key opinion leaders in urology presented on the ... renal masses while attendees had the opportunity to ... hands-on labs. Attendees at the Los Angeles, CA ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2
... 27 The American Stock Exchange(R),(Amex(R)) today lists ... ticker,symbol CUR. Neuralstem, Inc. is a biotechnology ... cell technology in the field of,regenerative medicine. ... Exchange," said,John McGonegal, Senior Vice President of Amex,s ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
... 27 DHA omega-3 innovator,Martek Biosciences announced today that ... featured in new Ricos(R) Cheese Sauce.,Sold to schools throughout ... of,DHA per serving in the standard foodservice packaging of ... 3.5 oz. single serve cup which contains 50 mg,of ...
Cached Biology Technology:NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 3
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
(Date:11/4/2014)... Think about the way our bodies are assembled during ... that they are supposed to become a nerve or ... the correct place and alignment? Researchers at the University ... In a new study, UM researchers describe the signaling ... neighbors, at the head-trunk region. Their discovery may have ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... knowledge of growth physiology. Incorrect treatment of bone fractures ... by technical deficiencies than by a misjudgment of the ... of treating fractures of the upper limb, Ralf Kraus ... University Medical Center Mannheim, report in the current issue ...
... 2011) The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical ... unveiled a new mammalian genetics track for PhD students. The ... JAX and Tufts. Combining the faculty and resources of the ... and the faculty and resources at JAX, with its emphasis ...
... University of Texas Health Science Center at Houston (UTHealth) ... study approved by the Food and Drug Administration to ... blood stem cells for traumatic brain injury in children. ... Memorial Hermann Hospital, UTHealth,s primary children,s teaching hospital. ...
Cached Biology News:Jackson Laboratory and Tufts University announce new Ph.D. track in mammalian genetics 2UTHealth studies cord blood stem cells for pediatric traumatic brain injury 2
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Biology Products: